The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration

Journal of the American College of Cardiology

Volumn 41, Issue 3, 2003, Pages 394-402

  Marmur, Jonathan D ^a,e   Anand, Sunil X ^b   Bagga, Ramanjit S ^b   Fareed, Jawed ^c   Pan, Chi Miau ^d   Sharma, Samin K ^b   Richard, Merwin F ^b  

^a SUNY Downstate Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d International Technidyne Corporation   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DALTEPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037419864     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02762-6     Document Type: Article

References (47)

1. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79: 1-17.
2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
3. Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992;82:406-13.
4. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
5. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecularweight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-8.
6. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19-24L.
7. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
8. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abclximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invasive Cardiol 2000;12 Suppl A:1-5A.
9. Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J 1990;63:18-21.
10. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-6.
11. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9.
12. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent - a pilot study in the setting of coronary, angioplasty. Thromb Haemost 1999;81:214-20.
13. Eriksson BI, Soderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401.
14. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-52.
15. Walenga JM, Bara L, Samama MM, Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin Thromb Hemost 1985;11:100-7.
16. Walenga JM, Fareed J, Hoppensteadt D, Emanuele RM. In vitro evaluation of heparin fractions: old vs. new methods. Crit Rev Clin Lab Sci 1986;22:361-89.
17. Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973;81:298-310.
18. Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 1987;46:527-37.
19. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335-43.
20. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
21. Zar JH. Biostatistical Analysis. 3rd edition. Saddle River, NJ: Prentice-Hall, Inc.
22. Cairns JA, Theroux P, Lewis HD, Jr., Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest 1998;114:611-33S.
23. Kloorwijk P, Lenderink T, Meij S, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999;20:1101-11.
24. Heran C, Morgan S, Kasiewski C, et al. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J Pharmacol 2000;389:201-7.
25. Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989;257:143-50.
26. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337: 688-98.
27. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation rime and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
28. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-3.
29. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
30. Narins CR, Hillegass WB, Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
31. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62.
32. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981;193:395-400.
33. Soons H, Janssen-Claessen T, Tans G, Hemker HC. Inhibition of factor XIa by antithrombin III. Biochemistry 1987;26:4624-9.
34. Mauron T, Lammle B, Wuillemin WA. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998;80:82-6.
35. Pieters J, Lindhout T, Willems G. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma. Blood 1990;76:549-54.
36. Mauray S, de Raucourt E, Talbot JC, Dachary-Prigent J, Jozefowicz M, Fischer AM. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan. Biochim Biophys Acta 1998;1387:184-94.
37. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996;22:77-91.
38. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
39. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993;23 Suppl 1:89-98.
40. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230-40.
41. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78: 2337-43.
42. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
43. Kitchen S, Iampietro R, Woolley AIM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999;82:1289-93.
44. Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xa monitoring: inter-assay variability. Thromb Haemost 2000;84:1122-3.
45. Abbate R, God AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33-6L.
46. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64-94S.
47. Teahon K, Bateman DN. A survey of intravenous drug administration by preregistration house officers. BMJ 1993;307:605-6.